Comparison of a new Light Diagnostics and the CMV Brite to an in-house developed human cytomegalovirus antigenemia assay.
Antigenemia, i.e. detection and quantification of human cytomegalovirus (HCMV) peripheral blood pp65-positive leukocytes, is still one of the two major assays available for diagnosis and monitoring of HCMV infections. To evaluate the performance of a new commercial assay under development (Light Diagnostics). To compare the performance of the new assay with a commercial assay (CMV Brite) already available on 300 blood samples from immunocompromised patients using as a reference the original in-house developed assay. Although 30 blood samples gave discrepant results among the 3 antigenemia assays, the Light Diagnostics detected an overall number of antigenemia-positive blood samples (sensitivity 84%) identical to that detected by CMV Brite (sensitivity 88%) and in-house assay (91/300, 30.3%). Problems of non-specific cytoplasmic staining were encountered with the CMV Brite assay in 219/300 (73%) blood samples. The Light Diagnostics assay provides results comparable to those of the reference assay both in terms of specificity and sensitivity (number of pp65-positive leukocytes).